Human African trypanosomiasis: Clinical presentation and immune response

Parasite Immunology

Volumn 26, Issue 11-12, 2004, Pages 469-476

  Sternberg, Jeremy M ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Clinical presentation; Human African trypanosomiasis; Immune response; Trypanosoma brucei

Indexed keywords

AFRICA; AFRICAN TRYPANOSOMIASIS; CLINICAL FEATURE; DISEASE CARRIER; DISEASE SEVERITY; EPIDEMIC; FLAGELLATE; GENETIC VARIABILITY; HUMAN; IMMUNE RESPONSE; INFECTION CONTROL; NONHUMAN; PRIORITY JOURNAL; REVIEW; TRYPANOSOMA BRUCEI; TSETSE FLY;

ANIMALS; HUMANS; SEVERITY OF ILLNESS INDEX; TRYPANOSOMA BRUCEI GAMBIENSE; TRYPANOSOMA BRUCEI RHODESIENSE; TRYPANOSOMIASIS, AFRICAN; TSETSE FLIES;

EID: 16244410117     PISSN: 01419838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0141-9838.2004.00731.x     Document Type: Review

References (76)

1. WHO. Control and Surveillance of African Trypanosomiasis. WHO Tech Report Series 1998; 881: 1-113.
2. Xong HV, Vanhamme L, Chamekh M et al. A VSG expression site-associated gene confers resistance to human serum in Trypanosoma rhodesiense. Cell 1998; 95: 839-846.
3. Gibson W. Will the real Trypanosoma brucei please step forward? Trends Parasitol 2002; 18: 486-490.
4. Fairbairn H & Godfrey DG. The local reaction in man at the site of infection with Trypanosoma rhodesiense. Ann Trop Medical Parasitol 1957; 51: 464-470.
5. Naessens J, Mwangi DM, Buza J & Moloo SK. Local skin reaction (chancre) induced following inoculation of metacyclic trypanosomes in cattle by tsetse flies is dependent on CD4 T lymphocytes. Parasite Immunol 2003; 25: 413-419.
6. Kennedy PGE. Human African Trypanosomiasis of the CNS: current issues and challenges. J Clin Invest 2004; 113: 496-504.
7. Barrett MP, Burchmore RJ, Stich A et al. The trypanosomiases. Lancet 2003; 362: 1469-1480.
8. Pays E, Vanhamme L & Perez-Morga D. Antigenic variation in Trypanosoma brucei: facts, challenges and mysteries. Curr Opin Microbiol 2004; 7: 369-374.
9. Vanhamme L, Pays E, McCulloch R & Barry JD. An update on antigenic variation in African trypanosomes. Trends Parasitol 2001; 17: 338-343.
10. Magez S, Stijlemans B, Baral T & De Baetselier P. VSG-GPI anchors of African trypanosomes: Their role in macrophage activation and induction of infection-associated immunopathology. Microbes Infection 2002; 4: 999-1006.
11. Mansfield JM. T-cell responses to the trypanosome variant surface glycoprotein: a new paradigm? Parasitol Today 1994; 10: 267-270.
12. Macaskill JA, Holmes PH, Jennings FW & Urquhart GM. Immunological clearance of 75Se-labelled Trypanosoma brucei in mice. III. Studies in animals with acute infections. Immunology 1981; 43: 691-698.
13. Turner CM & Barry JD. High frequency of antigenic variation in Trypanosoma brucei rhodesiense infections. Parasitology 1989; 99: 67-75.
14. Donelson JE. Antigenic variation and the African trypanosome genome. Acta Trop 2003; 85: 391-404.
15. Kazyumba G, Berney M, Brighouse G, Cruchaud A & Lambert PH. Expression of the B cell repertoire and autoantibodies in human African trypanosomiasis. Clin Exp Immunol 1986; 65: 10-18.
16. Lambert PH, Berney M & Kazyumba G. Immune complexes in serum and in cerebrospinal fluid in African trypanosomiasis. Correlation with polyclonal B cell activation and with intracerebral immunoglobulin synthesis. J Clin Invest 1981; 67: 77-85.
17. Lejon V, Buscher P, Magnus E, Moons A, Wouters I & Van Meirvenne N. A semi-quantitative ELISA for detection of Trypanosoma brucei gambiense specific antibodies in serum and cerebrospinal fluid of sleeping sickness patients. Acta Trop 1998; 69: 151-164.
18. Magez S, Stijlemans B, Radwanska M, Pays E, Ferguson MA & De Baetselier P. The glycosyl-inositol-phosphate and dimyristoylglycerol moieties of the glycosylphosphatidylinositol anchor of the trypanosome variant-specific surface glycoprotein are distinct macrophage-activating factors. J Immunol 1998; 160: 1949-1956.
19. Coller SP, Mansfield JM & Paulnock DM. Glycosylinositolphosphate soluble variant surface glycoprotein inhibits IFN-gamma-induced nitric oxide production via reduction in STAT1 phosphorylation in African trypanosomiasis. J Immunol 2003; 171: 1466-1472.
20. Sternberg MJ & Mabbott NA. Nitric oxide-mediated suppression of T cell responses during Trypanosoma brucei infection: soluble trypanosome products and interferon-gamma are synergistic inducers of nitric oxide synthase. Eur J Immunol 1996; 26: 539-543.
21. Bancroft GJ, Sutton CJ, Morris AG & Askonas BA. Production of interferons during experimental African trypanosomiasis. Clin Exp Immunol 1983; 52: 135-143.
22. MacLean L, Odiit M & Sternberg JM. Nitric oxide and cytokine synthesis in human African trypanosomiasis. J Infect Dis 2001; 184: 1086-1090.
23. Schleifer KW, Filutowicz H, Schopf LR & Mansfield JM. Characterization of T helper cell responses to the trypanosome variant surface glycoprotein. J Immunol 1993; 150: 2910-2919.
24. Hertz CJ, Filutowicz H & Mansfield JM. Resistance to the African trypanosomes is IFN-gamma dependent. J Immunol 1998; 161: 6775-6783.
25. Schopf LR, Filutowicz H, Bi XJ & Mansfield JM. Interleukin-4- dependent immunoglobulin G1 isotype switch in the presence of a polarized antigen-specific Th1-cell response to the trypanosome variant surface glycoprotein. Infect Immun 1998; 66: 451-461.
26. Donelson JE, Hill KL & El-Sayed NM. Multiple mechanisms of immune evasion by African trypanosomes. Mol Biochem Parasitol 1998; 91: 51-66.
27. Sternberg JM. Immunobiology of African trypanosomiasis. Chem Immunol 1998; 70: 186-199.
28. Schleifer KW & Mansfield JM. Suppressor macrophages in African trypanosomiasis inhibit T cell proliferative responses by nitric oxide and prostaglandins. J Immunol 1993; 151: 5492-5503.
29. Askonas BA. Macrophages as mediators of immunosuppression in murine African trypanosomiasis. Curr Top Microbiol Immunol 1985; 117: 119-127.
30. Magez S, Radwanska M, Beschin A, Sekikawa K & De Baetselier P. Tumor necrosis factor alpha is a key mediator in the regulation of experimental Trypanosoma brucei infections. Infect Immun 1999; 67: 3128-3132.
31. Magez S, Truyens C, Merimi M et al. P75 tumor necrosis factor-receptor shedding occurs as a protective host response during African trypanosomiasis. J Infect Dis 2004; 189: 527-539.
32. Cerami A & Beutler B. The role of cachectin/TNF in endotoxic shock and cachexia. Immunol Today 1988; 9: 28-31.
33. Enanga B, Burchmore RS, Stewart ML & Barrett MP. Sleeping sickness and the brain. Cell Mol Life Sci 2002; 59: 845-858.
34. Namangala B, De Baetselier P, Noel W, Brys L & Beschin A. Alternative versus classical macrophage activation during experimental African trypanosomosis. J Leukoc Biol 2001; 69: 387-396.
35. De Baetselier P, Namangala B, Noel W, Brys L, Pays E & Beschin A. Alternative versus classical macrophage activation during experimental African trypanosomosis. Int J Parasitol 2001; 31: 575-587.
36. Magez S, Geuskens M, Beschin A et al. Specific uptake of tumor necrosis factor-alpha is involved in growth control of Trypanosoma brucei. J Cell Biol 1997; 137: 715-727.
37. Kitani H, Black SJ, Nakamura Y et al. Recombinant tumor necrosis factor alpha does not inhibit the growth of African trypanosomes in axenic cultures. Infect Immun 2002; 70: 2210-2214.
38. Webb H, Carnall N, Vanhamme L et al. The GPI-phospholipase C of Trypanosoma brucei is nonessential but influences parasitemia in mice. J Cell Biol 1997; 139: 103-114.
39. Leal S, Acosta-Serrano A, Morita YS, Englund PT, Bohme U & Cross GA. Virulence of Trypanosoma brucei strain 427 is not affected by the absence of glycosylphosphatidylinositol phospholipase C. Mol Biochem Parasitol 2001; 114: 245-247.
40. MacLean L, Odiit M, Okitoi D & Sternberg JM. Plasma nitrate and interferon-gamma in Trypanosoma brucei rhodesiense infections: evidence that nitric oxide production is induced during both early blood-stage and late meningoencephalitic-stage infections. Trans R Soc Trop Med Hyg 1999; 93: 169-170.
41. Lejon V, Lardon J, Kenis G et al. Interleukin (IL)-6, IL-8 and IL-10 in serum and CSF of Trypanosoma brucei gambiense sleeping sickness patients before and after treatment. Trans R Soc Trop Med Hyg 2002; 96: 329-333.
42. Rhind SG, Sabiston BH, Shek PN et al. Effect of melarsoprol treatment on circulating IL-10 and TNF-alpha levels in human African trypanosomiasis. Clin Immunol Immunopathol 1997; 83: 185-189.
43. Okomo-Assoumou MC, Daulouede S, Lemesre JL, N'Zila-Mouanda A & Vincendeau P. Correlation of high serum levels of tumor necrosis factor-alpha with disease severity in human African trypanosomiasis. Am J Trop Med Hyg 1995; 53: 539-543.
44. Moore KW, de Waal Malefyt R, Coffman RL & O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19: 683-765.
45. Daulouede S, Bouteille B, Moynet D et al. Human macrophage tumor necrosis factor (TNF)-alpha production induced by Trypanosoma brucei gambiense and the role of TNF-alpha in parasite control. J Infect Dis 2001; 183: 988-991.
46. Kennedy PG. The pathogenesis and modulation of the post-treatment reactive encephalopathy in a mouse model of Human African Trypanosomiasis. J Neuroimmunol 1999; 100: 36-41.
47. Adams JH, Haller L, Boa FY, Doua F, Dago A & Konian K. Human African trypanosomiasis (T. b. gambiense): a study of 16 fatal cases of sleeping sickness with some observations on acute reactive arsenical encephalopathy. Neuropathol Appl Neurobiol 1986; 12: 81-94.
48. Hunter CA, Jennings FW, Kennedy PG & Murray M. Astrocyte activation correlates with cytokine production in central nervous system of Trypanosoma brucei brucei-infected mice. Laboratory Invest 1992; 67: 635-642.
49. Hunter CA & Kennedy PG. Immunopathology in central nervous system human African trypanosomiasis. J Neuroimmunol 1992; 36: 91-95.
50. Hunter CA, Gow JW, Kennedy PG, Jennings FW & Murray M. Immunopathology of experimental African sleeping sickness: detection of cytokine mRNA in the brains of Trypanosoma brucei brucei-infected mice. Infect Immun 1991; 59: 4636-4640.
51. Atouguia J & Costa J. Therapy of human African trypanosomiasis: current situation. Mem Inst Oswalde Cruz 1999; 94: 221-224.
52. Hunter CA, Jennings FW, Kennedy PG & Murray M. The use of azathioprine to ameliorate post-treatment encephalopathy associated with African trypanosomiasis. Neuropathol Appl Neurobiol 1992; 18: 619-625.
53. Jennings FW, Gichuki CW, Kennedy PG et al. The role of the polyamine inhibitor eflornithine in the neuropathogenesis of experimental murine African trypanosomiasis. Neuropathol Appl Neurobiol 1997; 23: 225-234.
54. Tsenova L, Bergtold A, Freedman VH, Young RA & Kaplan G. Tumor necrosis factor alpha is a determinant of pathogenesis and disease progression in mycobacterial infection in the central nervous system. Proc Natl Acad Sci USA 1999; 96: 5657-5662.
55. MacLean L, Odiit M & Sternberg JM. Intrathecal cytokine responses in Trypanosoma brucei rhodesiense sleeping sickness patients. Trans R Soc Trop Medical Hyg 2005.
56. Sarciron ME & Gherardi A. Cytokines involved in Toxoplasmic encephalitis. Scand J Immunol 2000; 52: 534-543.
57. Cua DJ, Hutchins B, LaFace DM, Stohlman SA & Coffman RL. Central nervous system expression of IL-10 inhibits autoimmune encephalomyelitis. J Immunol 2001; 166: 602-608.
58. Wery M & Burke J. Human 'healthy carriers' of Trypanosoma (brucei type) discovered by immunofluorescence test in the Republique Democratique du Congo. Trans R Soc Trop Med Hyg 1972; 66: 332-333.
59. Jamonneau V, Garcia A, Ravel S et al. Genetic characterization of Trypanosoma brucei gambiense and clinical evolution of human African trypanosomiasis in Cote d'Ivoire. Trop Med Int Health 2002; 7: 610-621.
60. Jamonneau V, Garcia A, Frezil JL et al. Clinical and biological evolution of human trypanosomiasis in Cote d'Ivoire. Ann Trop Med Parasitol 2000; 94: 831-835.
61. Jamonneau V, Ravel S, Garcia A et al. Characterization of Trypanosoma brucei s.l. infecting asymptomatic sleeping-sickness patients in Cote d'Ivoire: a new genetic group? Ann Trop Med Parasitol 2004; 98: 329-337.
62. Lapierre J & Coste M. [Contribution to the study of a Trypanosoma gambiense (Feo) strain isolated from a human case characterized by a duration of more than 20 years of clinically inapparent parasitemia]. Ann Parasitol Hum Comp 1963; 38: 757-782.
63. Ormerod WE. Taxonomy of the Sleeping Sickness Trypanosomes. J Parasitol 1967; 53: 824-830.
64. Buyst H. The epidemiology of sleeping sickness in the historical Luangwa valley. Ann Soc Belge Med Trop 1977; 57: 349-359.
65. MacLean L, Chisi JE, Odiit M et al. Severity of Human African Trypanosomiasis in East Africa is associated with geographic location, parasite genotype and host-inflammatory cytokine response profile. Infect Immun 2004; 72: 7040-7044.
66. Inverso JA, De Gee AL & Mansfield JM. Genetics of resistance to the African trypanosomes. VII. Trypanosome virulence is not linked to variable surface glycoprotein expression. J Immunol 1988; 140: 289-293.
67. Clayton CE. Trypanosoma brucei: influence of host strain and parasite antigenic type on infections in mice. Exp Parasitol 1978; 44: 202-208.
68. Murray M, Trail JC, Davis CE & Black SJ. Genetic resistance to African Trypanosomiasis. J Infect Dis 1984; 149: 311-319.
69. Kemp SJ, Iraqi F, Darvasi A, Soller M & Teale AJ. Localization of genes controlling resistance to trypanosomiasis in mice. Nat Genet 1997; 16: 194-196.
70. Iraqi F, Clapcott SJ, Kumari P, Haley CS, Kemp SJ & Teale AJ. Fine mapping of trypanosomiasis resistance loci in murine advanced intercross lines. Mamm Genome 2000; 11: 645-648.
71. Tabel H, Kaushik RS & Uzonna JE. Susceptibility and resistance to Trypanosoma congolense infections. Microbes Infect 2000; 2: 1619-1629.
72. Taylor KA & Mertens B. Immune response of cattle infected with African trypanosomes. Mem Inst Oswaldo Cruz 1999; 94: 239-244.
73. Espevik T, Figari IS, Shalaby MR et al. Inhibition of cytokine production by cyclosporin-A and Transforming Growth Factor-beta. J Exp Med 1987; 166: 571-576.
74. Bellone G, Aste-Amezaga G, Trinchieri G & Rodeck U. Regulation of NK-cell functions by TGF-beta1. J Immunol 1995; 155: 1066-1073.
75. Omer FM, Kurtzhals JA & Riley EM. Maintaining the immunological balance in parasitic infections: a role for TGF-beta? Parasitol Today 2000; 16: 18-23.
76. Ashworth TG & Goldsmid J. A re-assessment of the epidemiology and clinico-pathological features of human trypanosomiasis in Rhodesia. Cent Afr J Med 1975; 21: 1-12.